These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
10. Differences in IgG Antibody Responses following BNT162b2 and mRNA-1273 SARS-CoV-2 Vaccines. Montoya JG; Adams AE; Bonetti V; Deng S; Link NA; Pertsch S; Olson K; Li M; Dillon EC; Frosch DL Microbiol Spectr; 2021 Dec; 9(3):e0116221. PubMed ID: 34756093 [TBL] [Abstract][Full Text] [Related]
11. Effect of Different Disease-Modifying Therapies on Humoral Response to BNT162b2 Vaccine in Sardinian Multiple Sclerosis Patients. Pitzalis M; Idda ML; Lodde V; Loizedda A; Lobina M; Zoledziewska M; Virdis F; Delogu G; Pirinu F; Marini MG; Mingoia M; Frau J; Lorefice L; Fronza M; Carmagnini D; Carta E; Orrù V; Uzzau S; Solla P; Loi F; Devoto M; Steri M; Fiorillo E; Floris M; Zarbo IR; Cocco E; Cucca F Front Immunol; 2021; 12():781843. PubMed ID: 34956211 [TBL] [Abstract][Full Text] [Related]
12. Immunogenicity and safety of the mRNA-based BNT162b2 vaccine in systemic autoimmune rheumatic diseases patients. Pri-Paz Basson Y; Tayer-Shifman OE; Naser R; Tartakover Matalon S; Kimhi O; Gepstein R; Halperin T; Ziv-Baran T; Ziv A; Parikh R; Kivity S; Levy Y Clin Rheumatol; 2022 Dec; 41(12):3879-3885. PubMed ID: 36050514 [TBL] [Abstract][Full Text] [Related]
13. Type of mRNA COVID-19 vaccine and immunomodulatory treatment influence humoral immunogenicity in patients with inflammatory rheumatic diseases. Raptis CE; Berger CT; Ciurea A; Andrey DO; Polysopoulos C; Lescuyer P; Maletic T; Riek M; Scherer A; von Loga I; Safford J; Lauper K; Möller B; Vuilleumier N; Finckh A; Rubbert-Roth A Front Immunol; 2022; 13():1016927. PubMed ID: 36311791 [TBL] [Abstract][Full Text] [Related]
14. The persistence of anti-Spike antibodies following two SARS-CoV-2 vaccine doses in patients on immunosuppressive therapy compared to healthy controls-a prospective cohort study. Christensen IE; Jyssum I; Tveter AT; Sexton J; Tran TT; Mjaaland S; Kro GB; Kvien TK; Warren DJ; Jahnsen J; Munthe LA; Haavardsholm EA; Vaage JT; Grødeland G; Lund-Johansen F; Jørgensen KK; Syversen SW; Goll GL; Provan SA BMC Med; 2022 Oct; 20(1):378. PubMed ID: 36199139 [TBL] [Abstract][Full Text] [Related]
15. A prospective multicenter study assessing humoral immunogenicity and safety of the mRNA SARS-CoV-2 vaccines in Greek patients with systemic autoimmune and autoinflammatory rheumatic diseases. Tzioufas AG; Bakasis AD; Goules AV; Bitzogli K; Cinoku II; Chatzis LG; Argyropoulou OD; Venetsanopoulou AI; Mavrommati M; Stergiou IE; Pezoulas V; Voulgari PV; Katsimpari C; Katechis S; Gazi S; Katsifis G; Sfontouris CI; Georgountzos AI; Liossis SN; Papagoras C; Fotiadis DI; Skopouli FN; Vlachoyiannopoulos PG; Moutsopoulos HM J Autoimmun; 2021 Dec; 125():102743. PubMed ID: 34757289 [TBL] [Abstract][Full Text] [Related]
16. Depressive symptoms predict antibody titers after a second dose of the SARS-CoV-2 BNT162b2 vaccine among hospital workers in Japan. Kaneko H; Tsuboi H Brain Behav Immun; 2023 Jan; 107():414-418. PubMed ID: 36116693 [TBL] [Abstract][Full Text] [Related]
17. BNT162b2 vaccine-induced humoral and cellular responses against SARS-CoV-2 variants in systemic lupus erythematosus. Moyon Q; Sterlin D; Miyara M; Anna F; Mathian A; Lhote R; Ghillani-Dalbin P; Breillat P; Mudumba S; de Alba S; Cohen-Aubart F; Haroche J; Pha M; Boutin THD; Chaieb H; Flores PM; Charneau P; Gorochov G; Amoura Z Ann Rheum Dis; 2022 Apr; 81(4):575-583. PubMed ID: 34607791 [TBL] [Abstract][Full Text] [Related]
18. Antibody response to SARS-CoV-2 mRNA vaccines in patients with rheumatic diseases in Japan: Interim analysis of a multicentre cohort study. Kashiwado Y; Kimoto Y; Sawabe T; Irino K; Nakano S; Hiura J; Wang Q; Kawano S; Ayano M; Mitoma H; Ono N; Arinobu Y; Niiro H; Hotta T; Kang D; Akashi K; Ohshima S; Takeuchi T; Horiuchi T Mod Rheumatol; 2023 Mar; 33(2):367-372. PubMed ID: 35411376 [TBL] [Abstract][Full Text] [Related]
19. Healthcare Workers in South Korea Maintain a SARS-CoV-2 Antibody Response Six Months After Receiving a Second Dose of the BNT162b2 mRNA Vaccine. Choi JH; Kim YR; Heo ST; Oh H; Kim M; Lee HR; Yoo JR Front Immunol; 2022; 13():827306. PubMed ID: 35173736 [TBL] [Abstract][Full Text] [Related]
20. Antibody Responses to the BNT162b2 mRNA Vaccine in Healthcare Workers in a General Hospital in Japan: A Comparison of Two Assays for Anti-spike Protein Immunoglobulin G. Hibino M; Watanabe S; Kamada R; Tobe S; Maeda K; Horiuchi S; Kondo T Intern Med; 2022 Mar; 61(6):811-819. PubMed ID: 34980798 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]